Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Rani Therapeutics Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 ANNOUNCED UP TO $1.085 BILLION COLLABORATION WITH CHUGAI PHARMACEUTICAL CO. FOR MULTIPLE HIGH-VALUE THERAPEUTICS 

RANI THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS; PROVIDES CORPORATE UPDATE

SAN JOSE, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT WILL PRESENT PRECLINICAL DATA ON THE RANIPILL CAPSULE, THE COMPANY'S ORAL DELIVERY PLATFORM, AT OBESITYWEEK 2025 TAKING PLACE BOTH VIRTUALLY AND IN-PERSON ON NOVEMBER 4-7, 2025 IN ATLANTA, GEORGIA.

RANI THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ORAL DELIVERY OF SEMAGLUTIDE VIA THE RANIPILL CAPSULE AT OBESITYWEEK 2025

SAN JOSE, CALIF., OCT. 23, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THE APPOINTMENT OF ABRAHAM (ABE) BASSAN AND VASUDEV BAILEY, PH.D.

RANI THERAPEUTICS ANNOUNCES THE APPOINTMENTS OF ABE BASSAN AND VASUDEV BAILEY, PH.D. TO BOARD OF DIRECTORS

FINANCING LED BY SAMSARA BIOCAPITAL, L.P. (SAMSARA) WITH PARTICIPATION FROM ADDITIONAL INVESTORS, INCLUDING RA CAPITAL MANAGEMENT, ANOMALY, SPECIAL SITUATIONS FUNDS, INVUS AND MR.

RANI THERAPEUTICS ANNOUNCES CLOSING OF OVERSUBSCRIBED $60.3 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

SAN JOSE, CALIF., OCT. 17, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH CERTAIN INSTITUTIONAL AND ACCREDITED INVESTORS, WITH PARTICIPATION BY MIR IMRAN, THE COMPANY'S EXECUTIVE CHAIRMAN, TO PURCHASE SHARES OF ITS CLASS A COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), AND ACCOMPANYING WARRANTS TO PURCHASE CLASS A COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) (THE WARRANTS) THAT IS EXPECTED TO RESULT IN GROSS PROCEEDS OF APPROXIMATELY $60.3 MILLION, BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER OFFERING EXPENSES. THE PRIVATE PLACEMENT IS EXPECTED TO CLOSE ON OR ABOUT OCTOBER 21, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS. THE PRIVATE PLACEMENT OF THE SHARES OF CLASS A COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) WAS PRICED "AT-THE-MARKET" UNDER THE RULES AND REGULATIONS OF THE NASDAQ STOCK MARKET LLC. THE ACCOMPANYING WARRANTS WILL ONLY BE EXERCISED UPON RECEIPT OF STOCKHOLDER APPROVAL.

RANI THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $60.3 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET UNDER NASDAQ RULES

SAN JOSE, CALIF., OCT. 17, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A COLLABORATION AND LICENSE AGREEMENT WITH CHUGAI PHARMACEUTICAL CO., LTD. ("CHUGAI") FOR THE DEVELOPMENT AND COMMERCIALIZATION OF AN ORAL PRODUCT CONSISTING OF RANI'S ORAL DELIVERY TECHNOLOGY, THE RANIPILL, AND CHUGAI'S RARE DISEASE ANTIBODY IN DEVELOPMENT.

RANI THERAPEUTICS ANNOUNCES UP TO $1.085 BILLION COLLABORATION WITH CHUGAI PHARMACEUTICAL CO. FOR MULTIPLE HIGH-VALUE THERAPEUTICS INCLUDING RARE DISEASE AND IMMUNOLOGY PROGRAMS AND ANNOUNCES CONCURRENT OVERSUBSCRIBED $60.3 MILLION FINANCING

 ANNOUNCED STRATEGIC RESEARCH COLLABORATION WITH CHUGAI FOR TWO UNDISCLOSED MOLECULES   PRESENTED PRECLINICAL DATA DEMONSTRATING BIOEQUIVALENCE OF NOVEL, BISPECIFIC GLP-1/GLP-2 RECEPTOR AGONIST DELIVERED ORALLY VIA RANIPILL (RT-114) COMPARED TO SUBCUTANEOUS DELIVERY AT ENDO 2025   PHASE 1 STUDY FOR RT-114 FOR THE TREATMENT OF OBESITY EXPECTED TO INITIATE IN THE SECOND HALF OF 2025   ANNOUNCED A WARRANT INDUCEMENT TRANSACTION WITH AN EXISTING INVESTOR WITH GROSS PROCEEDS OF $4.3 MILLION   ANNOUNCED PRICING OF $3.0 MILLION REGISTERED DIRECT OFFERING  SAN JOSE, CALIF., AUG. 07, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDED A CORPORATE UPDATE.

RANI THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS; PROVIDES CORPORATE UPDATE

SAN JOSE, CALIF., JULY 15, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT WITH A SINGLE INSTITUTIONAL INVESTOR FOR THE PURCHASE AND SALE OF 4,354,000 SHARES OF RANI THERAPEUTICS' CLASS A COMMON STOCK AT A PURCHASE PRICE OF$0.40 PER SHARE AND PRE-FUNDED WARRANTS TO PURCHASE 3,146,000 SHARES OF CLASS A COMMON STOCK AT A PURCHASE PRICE OF$0.3999 IN A REGISTERED DIRECT OFFERING. THE EXERCISE PRICE OF EACH PRE-FUNDED WARRANT IS $0.0001 PER SHARE OF CLASS A COMMON STOCK.

RANI THERAPEUTICS HOLDINGS, INC. ANNOUNCES PRICING OF $3.0 MILLION REGISTERED DIRECT OFFERING

SAN JOSE, CALIF., JULY 14, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THAT IT WILL PRESENT PRECLINICAL DATA ON THE RANIPILL CAPSULE AT THE ENDOCRINE SOCIETY'S ANNUAL MEETING (ENDO 2025) TAKING PLACE JULY 12-15 IN SAN FRANCISCO, CA.

RANI THERAPEUTICS AND PROGEN ANNOUNCE LATE BREAKING PRESENTATION AT ENDO 2025 DEMONSTRATING BIOEQUIVALENCE OF NOVEL, BISPECIFIC GLP-1/GLP-2 RECEPTOR AGONIST DELIVERED ORALLY VIA RANIPILL COMPARED TO SUBCUTANEOUS DELIVERY

- RESEARCHAGREEMENT IS EVALUATING FEASIBILITY OF APPLYING RANI'S ORAL DELIVERY TECHNOLOGY TO CHUGAI'S ANTIBODIES AGAINST UNDISCLOSED TARGETS - SAN JOSE, CALIF., MAY 19, 2025 (GLOBE NEWSWIRE) -- RANI THERAPEUTICS HOLDINGS, INC. (RANI THERAPEUTICS OR RANI) (NASDAQ: RANI), A CLINICAL-STAGE BIOTHERAPEUTICS COMPANY FOCUSED ON THE ORAL DELIVERY OF BIOLOGICS AND DRUGS, TODAY ANNOUNCED THE COMPANY HAS ENTERED INTO A RESEARCH AGREEMENT ON 13TH AUGUST, 2024, FOR TWO MOLECULES WITH UNDISCLOSED TARGETS PROVIDED BY CHUGAI PHARMACEUTICAL CO., LTD.

RANI THERAPEUTICS ANNOUNCES RESEARCH AGREEMENT WITH CHUGAI

- ANNOUNCED PRECLINICAL DATA DEMONSTRATING THE BIOEQUIVALENCE OF RT-114, A BISPECIFIC GLP-1/GLP-2 RECEPTOR AGONIST (PG-102), DELIVERED ORALLY VIA THE RANIPILL CAPSULE, TO SUBCUTANEOUS ADMINISTRATION OF PG-102 -

Rani Therapeutics Holdings, Inc.

RANI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Rani Therapeutics Holdings, Inc.

RANI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RANI